{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:57Z","timestamp":1793190357553,"version":"4.5.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs). Sisonke participants were offered mRNA-1273 boosters between May and November 2022, when Omicron sub-lineages were circulating. Adverse events (AE) were self-reported, and co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths) were collected through national databases. We used Cox regression models with booster status as a time-varying covariate to determine the relative vaccine effectiveness (rVE) of the mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29\u201376%) against SARS-CoV-2 infection: 77% (95%CI 9\u201394%) in the one-Ad26.COV2.S dose group and 52% (95%CI 13\u201373%) in the two-dose group. Severe COVID-19 was identified in 148 unboosted Sisonke participants, and only one SHERPA participant with severe HIV-related immunosuppression. Of 11798 participants in the safety analysis, 228 (1.9%) participants reported 575 reactogenicity events within 7 days of the booster (most commonly injection site pain, malaise, myalgia, swelling, induration and fever). More reactogenicity events were reported among those with prior SARS-CoV-2 infections (adjusted odds ratio [aOR] 2.03, 95%CI 1.59\u20132.59) and less among people living with HIV (PLWH) (aOR 0.49, 95%CI 0.34\u20130.69). There were 115 unsolicited adverse events (AEs) within 28 days of vaccination. No related serious AEs were reported. In an immunogenicity sub-study, mRNA-1273 increased binding and neutralizing antibody titres and spike-specific T-cell responses 4 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status, and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron SARS-CoV-2 infections among HCWs and PLWH.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    The SHERPA study is registered in the Pan African Clinical Trials Registry (PACTR):\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\" xlink:type=\"simple\">PACTR202310615330649<\/jats:ext-link>\n                    and the South African National Clinical Trial Registry (SANCTR): DOH-27-052022-5778.\n                  <\/jats:p>","DOI":"10.1371\/journal.pgph.0003260","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:36:27Z","timestamp":1733405787000},"page":"e0003260","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study"],"prefix":"10.1371","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-234X","authenticated-orcid":true,"given":"Nigel","family":"Garrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarylee","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8611","authenticated-orcid":true,"given":"Nonhlanhla","family":"Yende-Zuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azwidhwi","family":"Takalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-4773","authenticated-orcid":true,"given":"Kubashni","family":"Woeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Bodenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phumeza","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-6600","authenticated-orcid":true,"given":"Imke","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waasila","family":"Jassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-0699","authenticated-orcid":true,"given":"Harry","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishen","family":"Seocharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackline","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentse","family":"Khuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-2167","authenticated-orcid":true,"given":"Millicent A.","family":"Omondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rofhiwa","family":"Nesamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-9756","authenticated-orcid":true,"given":"Roanne S.","family":"Keeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandeka","family":"Moyo-Gwete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Innes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zwelethu","family":"Zwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-3671","authenticated-orcid":true,"given":"Kathy","family":"Mngadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-9919","authenticated-orcid":true,"given":"William","family":"Brumskine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivashnee","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disebo","family":"Potloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlaa","family":"Badal-Faesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3969-8680","authenticated-orcid":true,"given":"Steve","family":"Innes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lombaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-8915","authenticated-orcid":true,"given":"Maphoshane","family":"Nchabeleng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizma","family":"Snyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Petrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-8131","authenticated-orcid":true,"given":"Elizabeth","family":"Spooner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logashvari","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dishiki","family":"Kalonji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-4668","authenticated-orcid":true,"given":"Vimla","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-8047","authenticated-orcid":true,"given":"Rebone","family":"Maboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mookho","family":"Malahleha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1346-7833","authenticated-orcid":true,"given":"Philip","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Allagappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7649-9055","authenticated-orcid":true,"given":"Gertruida M.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-2016","authenticated-orcid":true,"given":"Faeezah","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-4028","authenticated-orcid":true,"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-9398","authenticated-orcid":true,"given":"Wendy A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Anteyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Leav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameena","family":"Goga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SHERPA study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"16","key":"pgph.0003260.ref001","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"pgph.0003260.ref002","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and Heterologous Covid-19 Booster Vaccinations","volume":"386","author":"RL Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"10330","key":"pgph.0003260.ref003","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","article-title":"Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study","volume":"399","author":"L-G Bekker","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"pgph.0003260.ref004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"K Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"pgph.0003260.ref005","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"pgph.0003260.ref006","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMc2202061","article-title":"Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa","volume":"386","author":"G Gray","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pgph.0003260.ref007","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"KR Bewley","year":"2021","journal-title":"Nat Protoc"},{"issue":"27","key":"pgph.0003260.ref008","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1002\/sim.9001","article-title":"Assessing vaccine durability in randomized trials following placebo crossover","volume":"40","author":"J Fintzi","year":"2021","journal-title":"Stat Med"},{"issue":"2","key":"pgph.0003260.ref009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/ciac785","article-title":"Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults","volume":"76","author":"A Florea","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pgph.0003260.ref010","doi-asserted-by":"crossref","first-page":"e063935","DOI":"10.1136\/bmjopen-2022-063935","article-title":"Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans","volume":"12","author":"Y Young-Xu","year":"2022","journal-title":"BMJ Open"},{"key":"pgph.0003260.ref011","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study","volume":"11","author":"P Nordstrom","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"13","key":"pgph.0003260.ref012","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7113e2","article-title":"Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults\u2014VISION Network, 10 States, December 2021-March 2022","volume":"71","author":"K Natarajan","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"pgph.0003260.ref013","doi-asserted-by":"crossref","first-page":"e0261350","DOI":"10.1371\/journal.pone.0261350","article-title":"mRNA Covid-19 vaccines in pregnancy: A systematic review","volume":"17","author":"N Pratama","year":"2022","journal-title":"PLoS One"},{"issue":"15","key":"pgph.0003260.ref014","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2022.3271","article-title":"Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes","volume":"327","author":"M Magnus","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"pgph.0003260.ref015","doi-asserted-by":"crossref","first-page":"107549","DOI":"10.1016\/j.isci.2023.107549","article-title":"Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants","volume":"26","author":"V Gonzalez","year":"2023","journal-title":"iScience"},{"key":"pgph.0003260.ref016","unstructured":"Department of Statistics South Africa. The Status of Women\u2019s Health in South Africa: Evidence from selected indicators, 2022. Report No. 03-00-18 https:\/\/www.statssa.gov.za\/publications\/03-00-18\/03-00-182022.pdf (accessed on 16 August 2024)"},{"issue":"11","key":"pgph.0003260.ref017","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1473-3099(18)30428-6","article-title":"Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"S Delany-Moretlwe","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pgph.0003260.ref018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"G Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"pgph.0003260.ref019","article-title":"The impact of COVID-19 on use of maternal and reproductive health services and maternal and perinatal mortality","author":"R Pattinson","year":"2021","journal-title":"South Afr Health Rev"},{"issue":"5","key":"pgph.0003260.ref020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/QAD.0000000000002799","article-title":"HIV viral load and pregnancy loss: results from a population-based cohort study in rural KwaZulu-Natal, South Africa","volume":"35","author":"Y Moodley","year":"2021","journal-title":"AIDS"},{"issue":"9","key":"pgph.0003260.ref021","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/INF.0000000000003174","article-title":"Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women","volume":"40","author":"V Tukei","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pgph.0003260.ref022","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2214-109X(15)00275-2","article-title":"National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis","volume":"4","author":"H Blencowe","journal-title":"Lancet Glob Health 2016"},{"issue":"8","key":"pgph.0003260.ref023","doi-asserted-by":"crossref","first-page":"e2226335","DOI":"10.1001\/jamanetworkopen.2022.26335","article-title":"Durability of Heterologous and Homologous COVID-19 Vaccine Boosts","volume":"5","author":"C Tan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"pgph.0003260.ref024","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.medj.2021.12.004","article-title":"Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients","volume":"3","author":"N Khoo","year":"2022","journal-title":"Med"},{"issue":"10","key":"pgph.0003260.ref025","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination","volume":"385","author":"D Barouch","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"pgph.0003260.ref026","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciac495","article-title":"Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers","volume":"76","author":"R Sablerolles","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pgph.0003260.ref027","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"J Barros-Martins","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"pgph.0003260.ref028","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1093\/cid\/ciac237","article-title":"High Asymptomatic Carriage With the Omicron Variant in South Africa","volume":"75","author":"N Garrett","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"14","key":"pgph.0003260.ref029","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population Immunity and Covid-19 Severity with Omicron Variant in South Africa","volume":"386","author":"S Madhi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:36:42Z","timestamp":1733405802000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003260"}},"subtitle":[],"editor":[{"given":"Abram L.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0003260","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.07.24306760","asserted-by":"object"}]},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}